Matches in Nanopublications for { <http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#association> ?p ?o ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- association type Statement assertion.
- association label ""Do not initiate in patients with constipation ( 4.1 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment ( 4.2 Concomitant use of fluvoxamine ( 4.3 Alosetron hydrochloride tablets should not be initiated [see Warnings and Precautions ( 5.1 Alosetron hydrochloride tablets are contraindicated in patients with a history of the following: chronic or severe constipation or sequelae from constipation intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state Crohn's disease or ulcerative colitis diverticulitis severe hepatic impairment Concomitant administration of alosetron hydrochloride tablets with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1"" assertion.
- association object DOID_2089 assertion.
- association predicate treats assertion.
- association subject drugbank:DB00969 assertion.
- association provided_by NeuroDKG assertion.
- association relation MedicalContraindication assertion.